Rio Takeda of Japan shot a 3-under 69 to hold a two-shot lead after three rounds of the LPGA’s Blue Bay tournament on China’s ...

Japanese rookie Rio Takeda shot her third straight three-under-par 69 for a two-stroke lead heading into the final round of ...

Rio Takeda of Japan shot a 3-under 69 on Saturday to hold a two-shot lead after three rounds of the LPGA's Blue Bay ...

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Rio Takeda of Japan shot a 3-under 69 on Saturday to hold a two-shot lead after three rounds of the LPGA's Blue Bay ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 V ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Rio Takeda, a Japanese golfer, leads by two strokes in the LPGA Blue Bay tournament in Hainan after shooting a 69. Takeda seeks her second win after a sudden-death victory in Japan. She is closely ...

Takeda made it rain zebras at a Boston Celtics game Friday. The stunt saw 100 toy zebras parachute from the arena’s rafters ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...